Carbimazole Use in Hyperthyroidism and Immunotherapy‑Induced Thyroid Dysfunction

Indications & Contraindications

Carbimazole is an antithyroid medication indicated solely for the treatment of hyperthyroidism (e.g., Graves’ disease, toxic nodular goiter) and is not used for hypothyroidism management. 1, 2
Carbimazole must never be prescribed for hypothyroidism; levothyroxine is the appropriate replacement therapy for elevated TSH with low/normal FT4. 3

For symptomatic hyperthyroidism, start carbimazole together with a non‑selective beta‑blocker (propranolol or atenolol) to control adrenergic symptoms; carbimazole is rarely required for thyroid dysfunction caused by immune‑checkpoint‑inhibitor therapy. 1, 2

First‑line treatment of elevated FT4 with suppressed TSH during immune‑checkpoint‑inhibitor therapy is a beta‑blocker for symptom relief. 1, 2
Carbimazole should be added only if anti‑TSH‑receptor antibodies are positive and the patient has clinically significant hyperthyroid symptoms. 1, 2
Immune checkpoint inhibitor therapy should be withheld only when the patient is unwell with symptomatic hyperthyroidism while on carbimazole; otherwise treatment can continue. 1, 2
Monitoring schedule: measure TSH each treatment cycle for the first 3 months, then every second cycle thereafter in patients receiving anti‑PD‑1/PD‑L1 therapy. 1, 2

If hyperthyroidism persists after the initial 6‑week assessment, maintain carbimazole at 30 mg daily. 3
If the patient becomes hypothyroid, reduce the carbimazole dose to 5–10 mg daily or hold the drug temporarily. 3
During dose titration, repeat TSH and FT4 measurements every 6–8 weeks to guide further adjustments. 3